Although the probability of remission is much better in Herceptest 3+ breast carcinomas compared with tumours with lower levels of ERBB2, still about 50% of Herceptest 3+ breast carcinomas are resistant to trastuzumab. Here, ERBB2 is linked to breast carcinoma.